Latest PSYC Newsletter Highlighted by Exclusive Interview with Johns Hopkins Professor
Global Trac Solutions, Inc. (OTCPink: PSYC) announced the release of its September Microdose Monthly newsletter featuring an exclusive interview with Dr. Albert Garcia-Romeu of Johns Hopkins. This edition highlights ongoing clinical trials focusing on the efficacy of psilocybin for tobacco dependence and mental health conditions. CEO David Flores emphasized the importance of sharing such research to keep audiences informed about psychedelic medicine advancements. As regulatory attitudes shift, PSYC aims to position itself at the forefront of this emerging industry.
- Exclusive interview with Dr. Albert Garcia-Romeu, highlighting advances in psychedelic research.
- Focus on clinical trials researching psilocybin's efficacy for nicotine dependence.
- PSYC aims to lead in the emerging psychedelic medicine market.
- None.
LAS VEGAS, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) is pleased to announce that the second edition of its September Microdose Monthly newsletter, released this morning to subscribers, is headlined by an exclusive interview with Dr. Albert Garcia-Romeu, Assistant Professor for Johns Hopkins Center for Psychedelic & Consciousness Research.
Since obtaining regulatory approval in 2000 to reinitiate research with psychedelics, Johns Hopkins has been at the forefront of some of the most groundbreaking studies within the field of medicinal psychedelics. Highlighting their research within this space is their 2006 publication on the safety and enduring positive effects of a single dose of psilocybin that is considered a landmark study and one that in many respects sparked renewed interest in psychedelic research across the globe.
The interview, conducted by PSYC CEO, David Flores, dives into the different psychedelic-related clinical trials that Johns Hopkins is currently involved in, including their ongoing studies related to researching the efficacy of psilocybin for individuals who are tobacco or nicotine dependent, as well as the science behind what makes certain psychedelics so effective in treating specific mental health conditions.
Said Global Trac Solutions, CEO, David Flores: “I am extremely appreciative of the time Dr. Garcia-Romeu lent to us out of his busy schedule and for giving us an opportunity to share some of the exciting developments that are being examined at Johns Hopkins through their ongoing research with psychedelics. As Psychedelic Spotlight and Microdose Monthly continue to become a recognized and trusted source for news, information, and education within the emerging community of psychedelic medicine, keeping our audience informed on the many different advancements and developments that are being achieved within the science and research sector is of paramount importance. I am delighted to share this interview with our audience and look forward to continuing to develop and produce the thought-provoking, quality-driven content that truly captures the momentum I believe we are experiencing here in this industry.”
PSYC encourages those interested in receiving exclusive content highlighting the emerging medicinal psychedelic industry to subscribe today to its semi-monthly newsletter by visiting www.psychedelicspotlight.com.
About Global Trac Solutions, Inc. (OTCPink: PSYC)
At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.
Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Corporate Contact:
Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
(702) 239-1919
psyc@globaltracsolutions.com
OTCPINK: PSYC
